TRBC1-Targeting Antibody–Drug Conjugates for the Treatment of T Cell Cancers
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
July 2024
December 2022
Cell Specific Protein Degradation with Antibody Conjugated PROTACs
Written by: Genya Gorshtein, MSc Published: November 25, 2022 Contents Introduction General PROTAC Structure and Function Antibody-Conjugated PROTACs Developing AbPROTACs with De Novo Antibody Sequencing and Proteomics Introduction Small-molecule drug development is aimed at inhibiting disease-promoting protein function through occupancy-driven protein inhibition. A major caveat of [...]
September 2022
Antibody-Drug Conjugates as Anti-Cancer Therapeutics
Written by: Genya Gorshtein, MSc Published: September 14, 2022 Contents Introduction ADCs as Novel Anti-Cancer Chemotherapeutics Key Components of ADCs Future Generation of ADCs De Novo Protein Sequencing Applications in ADC Development Introduction An antibody-drug conjugate (ADC) is a monoclonal antibody (mAb) with a covalently attached [...]